Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Testosterone Nasal Gel in Hypogonadal Boys

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~ARM 1 (naïve patients): Participants who meet all of the following inclusion criteria will be eligible for participation in the study:~1. Hypogonadal boys;~2. Chronological age 12 to \<18 years;~3. No prior exposure to TRT;~4. Prepubertal~5. Parent/guardian and patient able to understand and provide signed informed consent;~ARM 2 (non-naïve patients): Participants who meet all of the following inclusion criteria will be eligible for participation in the study:~1. Hypogonadal boys with a bone age of ≥13 years (a historical value within the last 12 months will be acceptable);~2. Chronological age 12 to \<18 years;~3. Taking an existing TRT treatment dose;~4. Tanner Stage ≥3~5. Parent/guardian and patient able to understand and provide signed informed consent;~Exclusion Criteria:~ARM 1 (naïve patients) AND ARM 2 (non-naïve patients): Participants who meet any of the following criteria will be excluded from participation in the study:~1. Any active allergic condition or presentation of symptoms including allergic rhinitis;~2. An upper respiratory tract infection;~3. Use of any form of intranasal medication delivery other than periodic short-term (less than 3 days) use of sympathomimetic decongestants, within the last 3 months;~4. In the opinion of the Investigator, significant intercurrent disease of any type, in particular liver, kidney, heart disease, stroke, or psychiatric illness;~5. History of pituitary or hypothalamic tumors or history of any malignancy excluding basal cell or squamous cell carcinoma of the skin curatively treated by surgery;~6. History of nasal disorders, nasal or sinus surgery, nasal fracture within the previous 6 months or nasal fracture that caused a deviated anterior nasal septum surgery, mucosal inflammatory disorders, specifically Sjogren's syndrome;~7. History of severe adverse drug reactions to testosterone therapies;~8. Current treatment with other androgens (e.g., dehydroepiandrosterone \[DHEA\]), anabolic steroids, or other sex hormones;~9. Treatment with estrogens, gonadotropin-releasing hormone (GnRH) agonists, or growth hormone within the previous 12 months;~10. Treatment with drugs that interfere with the metabolism of testosterone, such as anastrozole, clomiphene, dutasteride, finasteride, flutamide, ketoconazole, spironolactone, or testolactone;~11. Diabetes mellitus;~12. Participation in any other research study during the conduct of this study or 30 days prior to the initiation of this study.

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Naive patients - ARM 1 (Type: EXPERIMENTAL): TRT naïve subjects, Tanner Stage of 0, receiving Testosterone Nasal Gel \[Natesto\] - Single dose of 5.5 mg Natesto on Day 1 and a single dose of 11 mg Natesto on Day 2
- Non-naive patients - ARM 2 (Type: EXPERIMENTAL): TRT non-naïve subjects (have had prior testosterone treatment), Tanner Stage \>/= 3, receiving Testosterone Nasal Gel \[Natesto\] - Single dose of 11 mg Natesto on Day 1. On Day 2, 11 mg dose of Natesto in the morning and 11 mg dose of Natesto 12 hours later

Based on this trial design, predict the completion outcome and termination type (if applicable).